Navigation Links
BioElectronics Announces Major Clinical Trials

Breast augmentation and cesarean section trials in conjunction with David

G. Genecov, MD, FACS, FAAP to begin immediately

FREDERICK, Md., May 28 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti- inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy specifically designed to speed healing, today announced world renowned plastic surgeon David G. Genecov will develop, institute and complete research studies on post-operative management of breast augmentation and cesarean section procedures. Both double blind randomized studies will be done in conjunction with other leading surgeons, obstetricians and gynecologists under Dr. Genecov's direction and supervision.

"We are very excited about these studies and believe they mark an important turning point for BioElectronics Corporation. The use of our products for post-breast augmentation care is already well established and continues to grow at a rapid pace," commented, Andy Whelan, CEO and President of BioElectronics Corporation. "The completion of a formal study by a surgeon of Dr. Genecov's caliber will further cement our position in this important and growing area. We are also very excited to be starting the trial for post- operative care for cesarean section. According to the National Center for Health Statistics, approximately one third of all babies in the United States are delivered by cesarean section up from less than approximately 20% just a decade ago. We believe this growing market represents a substantial market opportunity for our company."

Dr. David G. Genecov added, "Many general and plastic surgeons are starting to investigate the use of ActiPatch for post-surgical edema and pain control, but there has been little clinical data. We look forward to providing this important data to our colleagues over the coming months in order to determine the best post-operative procedures to assist patients in pain management and recovery."

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

About David G. Genecov, MD FACS FAAP

Dr. David G. Genecov is a native of Dallas, Texas. After finishing his undergraduate degree in the Plan II Honors Program at the University of Texas, he completed his medical training at the University of Texas Health Science Center in San Antonio. Upon completion of his general surgery residency at West Virginia University, Dr. Genecov became board certified in general surgery. He continued his education at Wake Forest University - Bowman Gray School of Medicine and completed his plastic surgery residency. He then completed a fellowship at the International Craniofacial Institute, Dallas, Texas, in Craniomaxillofacial surgery for adults and children with congenital and acquired deformities.

Widely published in both national and international literature, Dr. Genecov has also authored four medical book chapters. Dr. Genecov has received numerous awards for academic excellence, his surgical expertise and philanthropy. Most recently he was named one of the country's top surgeons by the independent Consumer Research Council of America for 2004-2005. He is Certified Member of the American Board of Plastic Surgery, a Certified Member of the American Board of Surgery, a Member of the American Society of Plastic Surgeons, a Member of the American Society of Maxillofacial Surgeons, a Member of the International Society of Craniofacial Surgeons, a Member of the Council of Health Care Advisors, and a Member of the American Academy of Anti-Aging Medicine. More information about Dr. Genecov can be seen at .

Information on ActiPatch and BioElectronics Corporation is available at the following websites:

-- U.S. Consumer

-- Podiatry:

-- Plastic Surgery: and

-- German orthopedic foot & ankle:

-- Italy and Switzerland:

-- Canada:

-- Netherlands:

-- Singapore & Malaysia:

-- BioElectronics Corp:

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email:

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email:

SOURCE BioElectronics Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
3. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
4. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
5. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
6. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
9. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
10. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
11. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
Post Your Comments:
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
(Date:11/25/2015)... Pennsylvania , November 25, 2015 - ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) --> ... Care Continuing Medical Education (CME) ... medical information products and services, will feature latest diagnostic imaging textbooks ...
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm ... appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto ... Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new ... systems. The new app features a more intuitive SleepScore™ that rates sleep quality on ... slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data to ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... ... 2015 , ... Since its launch in 2012, the Regenestem ... cell therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent ... (RTM). , Organizations are required to hold a registered trademark in order to ...
Breaking Medicine News(10 mins):